asa statement on glp 1 Glucagon-Like Peptide Receptor Agonists and Aspiration Risk Are Serious Anesthesia Risks of
Description
10.1073/pnas.1222051110 Proc
Lawsuits involving Ozempic often include evidence showing that drug manufacturers marketed directly to doctors without providing complete safety data
Current recommendations for patients with IBD Current evidence supports the use of GLP-1RAs in IBD patients who require the medication for an alternative approved indication, provided there is appropriate monitoring for potential side-effects
After 4 weeks, doses may be increased in 2.5 mg increments, as tolerated, up to a maximum of 15 mg once weekly
During this transition, the risk of infection may still be present until your levels stabilize
